Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

March 8, 2022

Study Completion Date

March 12, 2022

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DEVICE

TARA v3.1, only non-pharmacological self-management support

Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).

DEVICE

TARA v3.2, both non-pharmacological and pharmacological self-management support

Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).

Trial Locations (2)

28054

Clinical Research of Gastonia, Gastonia

29406

Lowcountry Lung and Critical Care, Charleston

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04795323 - Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD | Biotech Hunter | Biotech Hunter